New in Myeloma
Our "New in Myeloma" articles cover treatment option updates, coverage of advancements from major myeloma academic meetings, and more.
Exciting myeloma research in Australia has begun to see if targeting enzymes in the bone marrow can aid in myeloma destruction.
A drug combination called KRd is being used to treat primary plasma cell leukemia. But is it superior to other regimens?
BLENREP is making exciting progress after being pulled from the U.S. Market as an available myeloma treatment last year.
There were a multitude of myeloma studies at IMS 2023 which analyzed the strong connection of the native immune system and the efficacy of immunotherapies.
Myeloma researchers at Mount Sinai provided 22 patients with wearable tech to detect CRS. The results were remarkable.
Dr. Joshua Richter shares at IMS 2023 how myeloma infections are being monitored and prevented.
Dr. Kara Cicero shares the side effects of myeloma immunotherapies like CAR T and bispecific antibody therapy and how they're managed.
IDP-121 targets cMYC, a pivotal protein in tumorigenesis. The first patient has been successfully dosed.
Minimal residual disease testing on blood is now possible due to the test which has been validated for clinical use.
The newcomer myeloma drug iberdomide is combined with bortezomib and dexamethasone in a clinical trial and has a 100% response rate.
ASH 2023 HealthTree 360° Blood Cancer Research Reception: Advancing Your Research Using HealthTree Data and Technology
Dec 07 / 18:00 PST